DiagnosTear Technologies Inc. — Audit Report / Information 2025

Mar 31, 2026

NOTICE OF CHANGE OF AUDITOR

Notice Pursuant to Section 4.11 of
National Instrument 51-102 – Continuous Disclosure Obligations

TO: Grant Thornton Israel, Fahn Kanne& Co., Tel Aviv, Israel

AND TO: Doane Grant Thornton LLP., Toronto, Canada

DATED: March 30, 2026

Diagnostear Technologies Inc. (the “Company”) hereby provides notice (this “Notice”) pursuant to section 4.11 of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”) of a change in the auditor of the Company from Grant Thornton Israel, Fahn Kanne& Co of Tel Aviv, Israel (the “Predecessor Auditor”), to Doane Grant Thornton LLP. of Toronto, Canada (the “Successor Auditor”), and confirms the following:

1. at the request of the Company, the Predecessor Auditor tendered its resignation as auditor of the Company effective as of March 30, 2026;

2. the Successor Auditor has advised the Company of its agreement to be appointed as successor auditor of the Company, effective upon the Predecessor Auditor’s resignation;

3. the Board of Directors of the Company has appointed the Successor Auditor as successor auditor of the Company effective as of March 30, 2026, to fill the vacancy created by the resignation of the Predecessor Auditor and to perform the audit of the annual financial statements of the Company for the financial year ended December 31, 2025;

4. the audit committee of the Company has approved the resignation of the Predecessor Auditor and the appointment of the Successor Auditor;

5. there were no modified opinions expressed in the auditor’s reports of the Predecessor Auditor on the annual financial statements of the Company for the financial years ended December 31, 2024 and 2023; and

6. in the opinion of the Company, there are no “reportable events” (as that term is defined in NI 51-102).

The Company requests that each of the Predecessor Auditor and the Successor Auditor review this Notice and, on or before April 3, 2026, provide the Company with a letter addressed to the British Columbia, and Ontario Securities Commissions stating whether it (i) agrees, (ii) disagrees (and the reasons why), or (iii) has no basis to agree or disagree with the above statements in accordance with section 4.11 of NI 51-102.

[Remainder of page intentionally left blank.]

---

DATED as of the date first set forth above.

DIAGNOSTEAR TECHNOLOGIES INC.

Per: "Yifftach Biel"

Yifftach Biel
Chief Financial Officer

2